Has Ronald Plott, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,924,855 in general payments to Ronald Plott, MD across 960 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ronald Plott, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ronald Plott, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ronald Plott, MD

Dermatology · Fort Worth, TXNPI 1558569087

Payments from drug & device makers

$1,924,855in general payments, 2019–2025

Across 960 payments — averaging $2005.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi US Services Inc.$1.2M
Amgen$443K
Sun Pharmaceutical Industries Inc.$109K
AbbVie$55K
Incyte Corporation$33K
Galderma Laboratories, L.p.$24K
plus $56K from 41 others

$1,689in research payments, 2019–2025

Across 10 payments — averaging $168.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sanofi US Services Inc.$2K

What the payments were for

Consulting fees$36,05021%
Speaking & faculty fees$102,74259%
Travel & lodging$13,2568%
Food & beverage$21,83413%
Education$3240%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi US Services Inc.	70	$1,205,590
Amgen(2 entities)	17	$442,725
Sun Pharmaceutical Industries Inc.	136	$108,551
AbbVie(2 entities)	101	$54,711
Incyte Corporation	33	$33,419
Galderma Laboratories, L.p.	75	$23,629
Pfizer	66	$18,818
Ortho Dermatologics, A Division Of Bausch Health US, LLC	46	$12,885
Journey Medical Corporation	16	$5,958
UCB, Inc.	29	$5,182
EPI Health, LLC	12	$4,471
Merz North America, Inc.	6	$1,335
Sanofi	35	$899
Regeneron Healthcare Solutions, Inc.	33	$885
Lilly USA, LLC	22	$612
Johnson & Johnson	38	$583
Dermavant Sciences, Inc.	32	$547
Boehringer Ingelheim	5	$434
Misonix Inc	34	$403
Novartis	18	$398
LEO Pharma Inc.	18	$351
Arcutis Biotherapeutics, Inc.	21	$320
Organon	17	$301
Encore Dermatology Inc.	3	$228
Botanix SB Inc	7	$191
Almirall LLC	3	$169
Mayne Pharma Commercial LLC	10	$162
VYNE Pharmaceuticals Inc.	10	$158
Strata Skin Sciences, Inc.	4	$151
E.r. Squibb & Sons, L.L.C.	6	$134
Medimetriks Pharmaceuticals, Inc.	10	$117
Sanofi-aventis U.S. LLC	1	$100
Paratek Pharmaceuticals, Inc.	5	$98
Verrica Pharmaceuticals Inc.	3	$51
Biofrontera Inc.	2	$37
Genentech USA, Inc.	2	$35
Merck	1	$31
Medtronic	2	$30
Pierre Fabre Pharmaceuticals, Inc.	3	$25
DUSA Pharmaceuticals, Inc.	1	$24
Fresenius Kabi USA, LLC	1	$21
Tactile Systems Technology Inc	1	$16
Aclaris Therapeutics, Inc.	1	$16
Bristol Myers Squibb	1	$15
Angiodynamics, Inc.	1	$14
Cipher Pharmaceuticals US LLC	1	$14
Dermira, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Winlevi$88,870
ODOMZO$11,790
DUOBRII$11,178
ABSORICA LD$10,957
Cloderm$4,420
Rhofade$4,420
ABSORICA$4,400
Sitavig$3,882
Minolira 105mg$3,882
Minolira 135mg$3,882
Bimzelx$1,673
MINOLIRA EXTENDED RELEASE$1,076
SILIQ$672
Exelderm$633
Targadox$633
JUBLIA$625
ALTRENO$559
WYNZORA$538
BRYHALI$437
OPZELURA$370

How this compares

$1,924,855 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas →

Medicare billing

Part B allowed, 2024

$403,891

Medicare patients

1,168

Services billed

5,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	17	$142,867
Fluocinolone Acetonide	126	$5,778
Triamcinolone Acetonide	255	$4,263
Calcipotriene	28	$2,421
Fluorouracil	39	$2,346
CiclopiroxCiclopirox Olamine	101	$2,322
ValacyclovirValacyclovir Hcl	47	$1,943
Minocycline Hcl	76	$1,639
Clobetasol Propionate	51	$1,338
Metronidazole	33	$1,295
Tretinoin	16	$1,275
Desoximetasone	18	$878
Cephalexin	26	$541
Clindamycin Phosphate	13	$531
Hydroxychloroquine Sulfate	23	$445

Paid to pharmacies, not to this prescriber.

Other dermatology in Fort Worth

Patrick KeehanFort Worth$713K
Stephen TyringWebster$14.1M
Edward LainAustin$12M
Mark LeeSan Antonio$10.9M
John BrowningSan Antonio$10.7M
Craig TellerBellaire$7.7M
Patricia LeeWebster$7.2M
Jennifer CatherDallas$4.9M
Michael MigdenHouston$3.7M
Martin MenterDallas$3.7M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →